FiltersReset Filters

With box warnings

Without box warnings

Branded

Generic

8 results

bkemv
(eculizumab-aeeb)
Amgen Inc
Usage: BKEMV is indicated for treating paroxysmal nocturnal hemoglobinuria (PNH) to reduce hemolysis, atypical hemolytic uremic syndrome (aHUS) to inhibit complement-mediated thrombotic microangiopathy, and generalized myasthenia gravis (gMG) in adults who are anti-acetylcholine receptor (AchR) antibody positive. It is not for Shiga toxin E. coli related HUS.
empaveli
(Pegcetacoplan)
Apellis Pharmaceuticals, Inc.
Usage: EMPAVELI® is indicated for treating adult patients with paroxysmal nocturnal hemoglobinuria (PNH).
epysqli
(Eculizumab-aagh)
Teva Pharmaceuticals USA, Inc.
Usage: EPYSQLI is indicated for treating paroxysmal nocturnal hemoglobinuria (PNH) to reduce hemolysis, atypical hemolytic uremic syndrome (aHUS) to inhibit complement-mediated thrombotic microangiopathy, and generalized myasthenia gravis (gMG) in adults who are anti-acetylcholine receptor (AchR) antibody positive. Not for STEC-HUS.
izervay
(avacincaptad pegol)
Astellas Pharma US, Inc.
Usage: IZERVAY™ is indicated for the treatment of geographic atrophy (GA) associated with age-related macular degeneration (AMD).
soliris
(ECULIZUMAB)
Alexion Pharmaceuticals Inc.
Usage: SOLIRIS is indicated for treating paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), generalized myasthenia gravis (gMG) in patients six years or older who are anti-AChR antibody positive, and neuromyelitis optica spectrum disorder (NMOSD) in anti-AQP4 antibody positive adults.
syfovre
(Pegcetacoplan)
Apellis Pharmaceuticals, Inc.
Usage: SYFOVRE is indicated for the treatment of geographic atrophy (GA) due to age-related macular degeneration (AMD).
ultomiris
(ravulizumab)
Alexion Pharmaceuticals Inc.
Usage: ULTOMIRIS is indicated for treating paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS) in patients aged one month and older, generalized myasthenia gravis (gMG) in AChR antibody-positive adults, and neuromyelitis optica spectrum disorder (NMOSD) in AQP4 antibody-positive adults.
veopoz
(Pozelimab)
Regeneron Pharmaceuticals, Inc.
Usage: VEOPOZ is indicated for treating adult and pediatric patients aged 1 year and older with CD55-deficient protein-losing enteropathy (PLE), also referred to as CHAPLE disease.

Complement Inhibitor class drugs

bkemv

empaveli

epysqli

izervay

soliris

syfovre

ultomiris

veopoz